Dieta Brandsma
Overview
Explore the profile of Dieta Brandsma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Schie P, Huisman R, Wiersma T, Knegjens J, Jansen E, Brandsma D, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf027.
PMID: 40051659
Background: Novel systemic therapies, such as immunotherapy and targeted therapies, have shown better systemic disease control in the last decennium. However, the effect of these treatments on distant brain failure...
2.
Bortolot M, Huijs J, Brandsma D, Compter A, van Geel R, Hendriks L
Transl Lung Cancer Res
. 2025 Feb;
14(1):7-13.
PMID: 39958217
No abstract available.
3.
Reuvers M, Burgers V, Koekkoek J, Brandsma D, Compter A, Kouwenhoven M, et al.
Neurooncol Pract
. 2025 Feb;
12(1):113-121.
PMID: 39917748
Background: Low-grade gliomas (LGG) are among the most frequently occurring tumors in adolescent and young adult (AYA) patients (aged 18-39 years old at primary diagnosis). These tumors have a variable...
4.
Weller M, Le Rhun E, Tsamtsouri L, Dummer R, Guckenberger M, Ribi K, et al.
Lung Cancer
. 2024 Dec;
199:108069.
PMID: 39731865
No abstract available.
5.
Sol N, Kooi E, Pages-Gallego M, Brandsma D, Bugiani M, de Ridder J, et al.
Acta Neuropathol
. 2024 Sep;
148(1):35.
PMID: 39225924
No abstract available.
6.
NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases
Le Rhun E, Nayak L, Lim-Fat M, Ruda R, Pentsova E, Forsyth P, et al.
Neuro Oncol
. 2024 Aug;
27(2):455-465.
PMID: 39208403
Background: There are no validated tools for the clinical neurological assessment of patients with leptomeningeal metastases (LM). However, clinical examination during the course of the disease guides medical management and...
7.
Kloosterman D, Erbani J, Boon M, Farber M, Handgraaf S, Ando-Kuri M, et al.
Cell
. 2024 Aug;
187(19):5336-5356.e30.
PMID: 39137777
Tumors growing in metabolically challenged environments, such as glioblastoma in the brain, are particularly reliant on crosstalk with their tumor microenvironment (TME) to satisfy their high energetic needs. To study...
8.
van der Wel J, Boelens M, Jebbink M, Smulders S, Maas K, Luitse M, et al.
Neuro Oncol
. 2024 Aug;
26(12):2316-2327.
PMID: 39110039
Background: Diagnosis and treatment of leptomeningeal metastases (LM) in epidermal growth factor receptor mutation-positive (EGFRm +) non-small-cell lung carcinoma (NSCLC) is challenging. We aimed to identify resistance mechanisms (RM) to...
9.
Wilcox J, Chukwueke U, Ahn M, Aizer A, Bale T, Brandsma D, et al.
Neuro Oncol
. 2024 Jun;
26(10):1781-1804.
PMID: 38902944
Leptomeningeal metastases (LM) are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer,...
10.
Pluim D, Buitelaar P, de Jong K, Rosing H, Brandsma D, Huitema A, et al.
J Pharm Biomed Anal
. 2024 May;
245:116140.
PMID: 38701533
Ipilimumab is an immune checkpoint inhibitor of the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Ipilimumab has become part of the standard of care for different types of cancer. The efficacy of...